https://www.businesswire.com/news/home/20191202005135/en/

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec 2, 2019--

Dyno Therapeutics, a biotechnology company pioneering use of artificial intelligence in gene therapy, today announced a publication in the journal Science that demonstrates the power of a comprehensive machine-guided approach to engineer improved capsids for gene therapy delivery. The research was conducted by Dyno co-founders Eric D. Kelsic, Ph.D. and Sam Sinai, Ph.D., together with colleague Pierce Ogden, Ph.D., at Harvard’s Wyss Institute for Biologically Inspired Engineering and the Harvard Medical School laboratory of George M. Church, Ph.D., a Dyno scientific co-founder. The publication, entitled “Comprehensive AAV capsid fitness landscape reveals a viral gene and enables machine-guided design,” is available here. 1